N-(fluorenyl-9-methoxycarbonyl)leucine: a leumedin; RN given for (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 1549133 |
| CHEMBL ID | 149394 |
| SCHEMBL ID | 120560 |
| MeSH ID | M0219165 |
| Synonym |
|---|
| fmoc-l-leucine |
| smr001562137 |
| MLS002695993 , |
| (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid |
| AKOS015837135 |
| DIVK1C_001850 |
| fmoc-leu-oh |
| 35661-60-0 |
| CDS1_000810 |
| n-(9-fluorenylmethoxycarbonyl)-l-leucine |
| NCGC00164403-01 |
| MAYBRIDGE1_005562 |
| fmoc-leu-oh, >=97.0% |
| CHEMBL149394 |
| HMS557E18 |
| n-[(9h-fluoren-9-ylmethoxy)carbonyl]-l-leucine |
| F0295 |
| n-fmoc-l-leucine |
| NCGC00255677-01 |
| tox21_301495 |
| dtxsid0040751 , |
| dtxcid8020751 |
| cas-35661-60-0 |
| A822928 |
| (2s)-2-({[(9h-fluoren-9-yl)methoxy]carbonyl}amino)-4-methylpentanoic acid |
| n-((9h-fluoren-9-ylmethoxy)carbonyl)-l-leucine |
| kf18f70uf3 , |
| n-(fluorenyl-9-methoxycarbonyl)leucine |
| nsc 334290 |
| unii-kf18f70uf3 |
| einecs 252-662-7 |
| AKOS010398974 |
| fmoc-l-leu-oh |
| AM20060470 |
| n-(9-fluorenylmethyloxycarbonyl)-leucine |
| l-leucine, n-((9h-fluoren-9-ylmethoxy)carbonyl)- |
| fmoc-leucine |
| n-((9h-fluoren-9-ylmethoxy)carbonyl)-l-leucine, (-)- |
| (2s)-2-((((9h-fluoren-9-yl)methoxy)carbonyl)amino)-4-methylpentanoic acid |
| STL466197 |
| M03365 |
| SCHEMBL120560 |
| (s)-2-((((9h-fluoren-9-yl)methoxy)carbonyl)amino)-4-methylpentanoic acid |
| n-(9-fluorenylmethyloxycarbonyl)leucine |
| fmoc-l-leu--oh |
| fmoc-leu |
| n-9-fluorenylmethoxycarbonyl-l-leucine |
| fmoc-l-leu |
| n-fmoc leucine |
| fmoc leucine |
| n-[(9-fluorenyl)-methoxycarbonyl]-l-leucine |
| n-[(9-fluorenyl)methoxycarbonyl]-l-leucine |
| n-[(9h-fluoren-9-ylmethoxy)carbonyl]leucine # |
| n-.alpha.-fmoc-l-leucine |
| l-leucine, n-[(9h-fluoren-9-ylmethoxy)carbonyl]- |
| n-9-fluorenylmethyloxycarbonyl-l-leucine |
| J-300159 |
| (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methyl-valeric acid |
| (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methyl-pentanoic acid |
| bdbm115093 |
| (2s)-2-[[9h-fluoren-9-ylmethoxy(oxo)methyl]amino]-4-methylpentanoic acid |
| cid_1549133 |
| STR09711 |
| Q-101698 |
| (((9h-fluoren-9-yl)methoxy)carbonyl)-l-leucine |
| AC-24092 |
| n-alpha-(9-fluorenylmethyloxycarbonyl)-l-leucine (fmoc-l-leu-oh) |
| CCG-249806 |
| sr-05000000436 |
| SR-05000000436-2 |
| D71213 |
| CS-W019808 |
| fluoren-9-yl n-(1-carboxy-3-methylbutyl)carbamate |
| n-(fluoren-9-ylmethoxycarbonyl)-l-leucine |
| (s)-2-(((9h-fluoren-9-yl)methoxy)carbonylamino)-4-methylpentanoic acid |
| l-leucine, fmoc protected |
| Q27282223 |
| EN300-74035 |
| HY-101064 |
| Z1123720065 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 3.5574 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 11.2202 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| BRCA1 | Homo sapiens (human) | Potency | 11.2202 | 0.8913 | 7.7225 | 25.1189 | AID624202 |
| pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 7.9433 | 0.0251 | 27.9203 | 501.1870 | AID651751 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 2.3013 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 21.8724 | 0.1737 | 34.3047 | 61.8120 | AID1346859 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 21.8724 | 0.1737 | 34.3047 | 61.8120 | AID1346859 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 1.4050 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 9.8287 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID1259381; AID743042; AID743054 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 65.7208 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259378 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 7.4046 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 68.5896 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 24.3392 | 0.0002 | 14.3764 | 60.0339 | AID588533; AID720691 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 2.2957 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 50.1187 | 0.0008 | 17.5051 | 59.3239 | AID588544 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 16.9554 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 22.0692 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982; AID720659 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 12.7160 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID1259383; AID743069; AID743075; AID743079; AID743080; AID743091 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 31.6228 | 0.0010 | 24.5048 | 61.6448 | AID588534 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 9.5720 | 0.0010 | 19.4141 | 70.9645 | AID588536; AID743094; AID743140; AID743191 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 2.0400 | 0.0007 | 23.0674 | 1,258.9301 | AID651777; AID743085; AID743122 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 2.7306 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 43.9307 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 2.3109 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 66.6712 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 14.3372 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID720636 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 3.0638 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 30.6379 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 3.0638 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 15.8489 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 14.3887 | 0.0119 | 17.9420 | 71.5630 | AID651632; AID720516 |
| Ataxin-2 | Homo sapiens (human) | Potency | 12.1972 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Nuclear hormone receptor family member daf-12 | Caenorhabditis elegans | EC50 (µMol) | 67.5410 | 4.2360 | 4.2360 | 4.2360 | AID743059 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1669234 | Non-competitive inhibition of human recombinant-Sialin expressed in HEK293 cells assessed as reduction in [3H]Neu5Ac uptake by measuring Km level at 10 uM incubated for 15 mins by liquid scintillation counting method (Rvb = 1.6 +/- 0.3 mM) | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin. |
| AID1669233 | Non-competitive inhibition of human recombinant-Sialin expressed in HEK293 cells assessed as reduction in Vmax for [3H]Neu5Ac uptake at 10 uM incubated for 15 mins by liquid scintillation counting method relative to control | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin. |
| AID1669228 | Inhibition of human cystinosin at 100 uM relative to control | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin. |
| AID1669222 | Inhibition of human recombinant-Sialin expressed in HEK293 cells assessed as reduction in [3H]Neu5Ac uptake at 30 to 300 uM incubated for 15 mins by liquid scintillation counting method | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin. |
| AID1669223 | Inhibition of human recombinant-Sialin expressed in HEK293 cells assessed as reduction in [3H]Neu5Ac uptake at 30 uM incubated for 15 mins by liquid scintillation counting method | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin. |
| AID1669229 | Inhibition of human recombinant-Sialin expressed in HEK293 cells assessed as reduction in [3H]Neu5Ac uptake at 100 uM incubated for 15 mins by liquid scintillation counting method | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin. |
| AID1669237 | Non-competitive inhibition of human recombinant-Sialin expressed in HEK293 cells assessed as reduction in [3H]Neu5Ac uptake incubated for 15 mins by liquid scintillation counting method | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin. |
| AID198129 | Mouse ribonucleotide reductase (mRR) activity was determined by relative dissociation constant which was assayed for binding activity to mR1 | 2002 | Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4 | Affinity-driven selection of tripeptide inhibitors of ribonucleotide reductase. |
| AID91169 | In vitro ability to inhibit the adhesion of neutrophil activated by tumor necrosis factor (alpha-TNF) to serum-coated plastic wells. | 1995 | Journal of medicinal chemistry, May-12, Volume: 38, Issue:10 | Fluorenylalkanoic and benzoic acids as novel inhibitors of cell adhesion processes in leukocytes. |
| AID1669230 | Substrate activity at EGFP-fused human Sialin L22G/L23G mutant expressed in HEK293 cells in acidic medium using tritiated compound at 2 to 100 uM by liquid scintillation counting method | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin. |
| AID1669239 | Inhibition of human recombinant-Sialin expressed in HEK293 cells assessed as reduction in [3H]Neu5Ac transport at 120 uM pre-incubated for 15 mins at pH 5.5 followed by 15 or 30 mins wash at pH 7 at room temperature by liquid scintillation counting method | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin. |
| AID1669242 | Lipophilicity, log Pof the compound | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin. |
| AID1669227 | Inhibition of human LYAAT1 at 100 uM relative to control | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.85) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (6.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (93.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||